Twenty-two urine specimens reported by military drug-testing laboratories for the presence of high concentrations of amphetamine only were subject to further analysis for the presence of methamphetamine. The 22 urine specimens had concentrations of amphetamine in the range of 28,028 to 241,142 ng/mL. The specimens were also assayed for the respective isomeric ratio of d (S ) and l (R) amphetamine and methamphetamine. The results suggest that urine specimens containing high concentrations of amphetamine in which the urine concentration ratio of methamphetamine to amphetamine is less than 0.5% with similar isomeric distribution of d-(S ) and l-(R) amphetamine and methamphetamine, respectively, may not necessarily indicate polydrug use.
Introduction
An individual with no documented history of drug abuse and self-reported abstinence of drug use had a positive urine analysis by immunoassay and gas chromatography-mass spectrometry (GC-MS) for amphetamine at 98,000 ng/mL and methamphetamine at 275 ng/mL. The isomeric ratio was 75% d-amphetamine (S) and 83% d-methamphetamine (S). The individual denied use of amphetamine and methamphetamine. A background investigation supported no history of drug abuse. During administrative and legal review, the possibility of a prescription medication substitution arose as the basis for the positive urine analysis. A sibling with a documented history of prescribed Adderall ® had recently moved in with the accused on a temporary basis pending relocation of her family. Believing that the accused was no longer using Flexeril ® , the sibling reportedly discarded the few tablets of Flexeril in the accused prescription bottle and replaced them with her generic 20-mg Adderall tablets that she had transported in a cigarette case. The accused had a valid prescription for Flexeril, on an as-needed basis, for back pain. Each day, over the course of the weekend prior to the urine analysis, the individual took multiple doses of what she believed to be Flexeril for acute back pain relief. There was documentation of phone messages to her physician that the medication, which the accused believed to be Flexeril, was providing no pain relief. The generic Adderall and prescribed Flexeril had nearly similar shape and color characteristics. Subsequent analysis of one of the Adderall tablets indicated 80% d-amphetamine (S). If correct, the mistaken ingestion of Adderall would explain the high concentration of isomeric amphetamine encountered, but what was the source of the low level isomeric methamphetamine? Is it possible to encounter low concentrations of methamphetamine in the presence of high amphetamine concentrations of similar isomeric ratios in urine analysis specimens to collaborate the proposed scenario?
Materials and Methods

Specimen collection
Urine specimens (slated for discard post one year frozen storage) were solicited from the military drug testing laboratories. Specimens solicited were those urine specimens reported as positive for the presence of amphetamine only and at approximate concentrations equal to or greater than 25,000 ng/mL. No personal information was associated with the specimens obtained.
purchased from Fisher Scientific or Aldrich Chemical and of high-performance liquid chromatography (HPLC) grade.
Specimen preparation and analysis
For amphetamine-methamphetamine analysis, 2 mL each of urine specimens, calibrators, controls, and negative specimens were used in the extraction. A calibration curve was prepared at 2, 5, 20, 50, 200, 500, and 1000 ng/mL. Dilutions, as required using negative urine, were made to bring amphetamine concentrations within range. Methamphetamine concentrations were determined from undiluted specimens.
To eliminate the possibility of methamphetamine detection due to the presence of nondeuterated methamphetamine in the methamphetamine-d 14 internal standard, the initial amphetamine-methamphetamine analysis was conducted using only amphetamine-d 11 as the internal standard. Once the presence of methamphetamine was confirmed by GC-MS, quantitative analysis of methamphetamine was conducted using methamphetamine-d 14 .
Deuterated internal standard (1000 ng/mL) was added to each 2-mL aliquot of specimen. Specimens were made alkaline with the addition of 200 µL of concentrated KOH. Following the addition of 5 mL of chlorobutane, the specimens were gently rotated for 15 min, then centrifuged for 10 min at 1920 × g, and the upper organic layer transferred to clean tubes. Following the addition of 100 µL of 1% HCl, the specimens were evaporated to dryness under nitrogen at 50°C. The dried extracts were derivatized with 25 µL of chorodifluoroacetic anhydride and 100 µL of ethyl acetate. Specimens were vortex mixed and incubated for 15 min at 70°C. Following incubation, the extracts were evaporated to dryness, reconstituted with 50 µL of ethyl acetate, vortex mixed, and transferred to injection vials for GC-MS analysis.
For isomeric analysis, 2 mL each of urine specimen, calibrator, controls, and negative sample were used in the extraction. A one-point calibration at 500 ng/mL was used against a 50% d/l (S/R) isomer ratios of amphetamine and methamphetamine. Internal standard (100 ng/mL) of d/l-(S/R)-amphetamine-d 11 and d/l-(S/R)-methamphetamine-d 14 was added to each tube. Specimens were made alkaline with the addition of 200 µL of concentrated KOH. Following the addition of 5 mL of chlorobutane, the specimens were gently rotated for 15 min, then centrifuged for 10 min at 3000 rpm, and the upper organic layer transferred to clean tubes. Following the addition of 100 µL of 1% HCl, the specimens were evaporated to dryness under nitrogen at 50°C. A previously published method (1) using the chiral derivitization reagent R-MTPAC was used to separate the isomers of methamphetamine and amphetamine into chromatographically distinguishable diasteromers.
GC-MS analysis
Amphetamine and methamphetamine analysis. An Agilent 6890 GC coupled to a 5973 MSD was used for the detection and confirmation of amphetamine and methamphetamine. An Agilent DB-5MS (20 m × 0.18-mm i.d., 0.18-µm film thickness) column was used for separation. Injections were analyzed with a 4-mm straight inlet liner with deactivated glass wool in the pulse split mode (10:1) and a pulse pressure of 35 psi for 0.9 min. Helium flow was constant at 1.0 mL/min. The injection port temperature was 175°C with an initial GC oven program of 70°C with a 1.0-min hold. Temperature was ramped at 20°C/min to 230°C with a final ramp of 50°C/min to 300°C followed by a 1.6-min hold. The MS acquisition was operated in the selected ion monitoring mode ( Criteria for GC-MS acceptance. The retention time (t R ) of the analyte in the specimens and controls must be within (±) 2% of the t R of the analyte in the calibrators. The ion ratios for the analyte in the specimens and controls must be within (±) 20% of the ion ratios for the calibrator analyte. The negative control should be less than the concentration established as the lower limit of quantitation, and the positive controls must be within (±) 20% of the laboratory established target concentration. The GC-MS lower limit of detection for amphetamine and methamphetamine was less than 2 ng/mL, and the lower limit of quantitation was 2 ng/mL.
Results and Discussion
A total of 22 specimens were analyzed. The total amphetamine concentration ranged from 28,028 to 241,142 ng/mL. The total methamphetamine concentration detected ranged from 3.8 to 275 ng/mL. Isomeric methamphetamine determinations were conducted only on specimens where the total methamphetamine concentration approximated 19 ng/mL or greater.
As noted in Table I , data from the 22 urine specimens with an amphetamine concentration greater than 25,000 ng/mL were compiled. The following correlates were noted: 1. There does not appear to be a correlation between the amphetamine concentration and the subsequent methamphetamine concentration detected. 2. The only consistent correlation is the ratio of methamphetamine to amphetamine that is below 0.5%. 3. Seven urine specimens with a methamphetamine concentration approximately 19 ng/mL or greater were analyzed for isomeric correlation between the amphetamine and methamphetamine isomers.
Of the seven specimens subject to isomeric analysis: within the variance of the isomeric analysis, there was a correlation in the ratio of d/l-(S/R)-methamphetamine to the d/l-(S/R)-amphetamine ratio for six of the seven urine specimens analyzed, and one urine sample showed an amphetamine to methamphetamine isomeric correlation outside the normal range of variance namely a 70% d-amphetamine (S) and an 87% d-methamphetamine (S) correlate.
The current study is not an attempt to distinguish knowing versus unknowing ingestion of Adderall or illicit amphetamine use but rather to determine if urine specimens containing high concentrations of amphetamine also demonstrate the presence of low concentrations of methamphetamine. It does appear that low urine levels of methamphetamine may be associated with high urinary concentrations of amphetamine. The two distinctive correlates in this limited analysis are first, the ratio of methamphetamine to amphetamine is less than 0.5%, and second, there appears to be a similar isomeric ratio of d/l (S/R) between the amphetamine and methamphetamine encountered. Limitations in quantitative and isomeric analysis were based upon the analyte recovery with acceptable chromatography, peak symmetry, and mass ion ratios.
The source of the urine methamphetamine cannot be determined in this limited study. Two considerations are offered. First, is the small amount of methamphetamine found in the urine a minor methamphetamine by-product component from the amphetamine manufacture process? Second, does a minor pathway of methylation exist in the metabolism and elimination of high blood concentrations of amphetamine? In a publication by Cone et al. (2) , individuals receiving codeine-based medications are known to excrete hydrocodone via a minor metabolic pathway. Cone and co-workers (2) presented data suggesting that hydromorphone may also be excreted in the urine through a minor metabolic pathway of conversion of morphine to hydromorphone. This observation has been subsequently validated in two other publications (3, 4) . Cone et al. (2) suggest that in the interpretation of low urinary concentrations of hydromorphone in morphine-treated pain patients, the presence of hydromorphone should not be considered as conclusive evidence of hydromorphone misuse. Perhaps a similar degree of caution should be considered in urine specimens where low concentrations of methamphetamine are detected in the presence of high concentrations of amphetamine. This preliminary work perhaps suggests that the presence of low urinary concentrations of methamphetamine should not be considered as conclusive evidence of methamphetamine abuse when elevated urine amphetamine concentrations are encountered if the ratio of methamphetamine to amphetamine is below 0.5% and there is a similar isomeric ratio of methamphetamine and amphetamine analytes in the urine. Validation of these observations is requested by other laboratories encountering high concentrations of urinary amphetamine or specimens from individuals under controlled amphetamine administration. Confirmation of these observations would be pertinent to the interpretation of toxicological analyses by pathologists, toxicologists, medical review officers, and drug counselors.
